LifeScan

LifeScan, Inc. is a diagnostic systems manufacturer with products focusing on the diabetes market, specifically blood glucose monitoring systems.

LifeScan was established in 1981.^[3] It was acquired by Johnson & Johnson (J&J) in 1986,^[2][4] and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018.^[1] The divestiture completed in October 2018.^[1][5]

LifeScan manufactures and markets the OneTouch Ultra and OneTouch Verio families of products for home use.^[1] The company philosophy is to "create a world without limits for people with diabetes." During its existence, LifeScan revolutionized blood glucose monitoring by introduction of its "One Touch" systems. Originally, the measurement was made using a test strip which changed color depending on the glucose content of a blood sample, and LifeScan rose to become the world-leading producer of such systems in the early 1990s. Later, the measurement technology was changed to electrochemistry, but LifeScan maintained a leading position in the industry.

LifeScan has facilities in Inverness, Scotland; Burnaby, British Columbia, Canada; and Cabo Rojo, Puerto Rico. Animas Corporation of West Chester, Pennsylvania, which produced insulin pumps for people with diabetes, was acquired by Johnson & Johnson in 2006 and now closed, reported to LifeScan.

LifeScan, which employed 2400 people as of early 2018, was the central part of J&J's diabetes device business.^[2] J&J announced plans to exit from the diabetes device market in 2017, including divesting LifeScan.^[2] In January 2018, there were reports of Chinese investors expressing interest in purchasing the company for US$3 to 4 billion, while in March, Platinum Equity offered the far smaller sum of US$2.1 billion for the unit.^[2][6]

• LifeScan
• LifeScan Diabetes Institute
• OneTouch